Content Type: Article

  • The EU’s Draft Regulations on SEP Licensing: Additional Context from the Impact Assessment Report

    The EU’s Draft Regulations on SEP Licensing: Additional Context from the Impact Assessment Report

    ARTICLE / CLIENT ALERT

    The EU’s Draft Regulations on SEP Licensing: Additional Context from the Impact Assessment Report

    April 17, 2023

    Read time: 4 min

    Key takeaways
    Overview

    We recently reported on the European Commission’s leaked draft regulations concerning the fair, reasonable and non-discriminatory (FRAND) licensing of standard essential patents (SEPs). Since the publication of that piece, we have reviewed a 245-page Impact Assessment Report from the European Commission that offers further context on the draft regulations and reveals an interesting feature that was considered but ultimately not included in the leaked draft.

    In depth

    At a high level, the draft regulations would establish a new FRAND regulatory regime with the following features:

    1. A “competence center” at the European Union Intellectual Property Office that will provide information on FRAND negotiations, relevant case law, etc.
    2. A SEP registry and essentiality checks conducted by the competence center. Registration would be mandatory before the patent owner could enforce or license its SEPs in Europe, but an essentiality check would not be.
    3. A mediation-style determination of the FRAND rate that applies between a specific SEP owner and implementer (known as “conciliation”). This would also be mandatory before enforcement in a European court.
    4. A process to determine the aggregate FRAND royalty for an entire standard, largely driven by the SEP owners.

    The report refers to those features as Options 1 through 4, ordered “from the least to the most ambitious.” The four options are incremental—that is, each subsequent option combines with and incorporates the previous one. The European Commission analyzed the impact of each option on SEP owners, implementers, courts and patent offices and ultimately settled on Option 4 as the preferred choice.

    The report also discusses a further option that was not included in the draft regulations: Option 5, which would establish a “SEP clearing house” to act as “a one-stop-shop facility for implementers” by giving the aggregate royalty determination of Option 4 a binding effect. According to this option, any implementer could obtain a license from all SEP owners on a given standard by depositing royalty payments into an escrow account. SEP owners would be tasked with determining a fair apportionment of the royalties among themselves. Although the report does not state exactly why Option 5 was not included in the draft, it notes several downsides that likely influenced this decision. As to implementers, the European Commission worried that the aggregate royalty would be too high and that the ease of obtaining royalties through the clearing house would encourage greater participation among SEP owners, thus increasing the effective royalty burden on implementers. As to SEP owners, the European Commission expressed skepticism that SEP owners would ever reach an agreement on apportionment.

    Although ambitious, the Option 5 clearing house is not without precedent. As the report acknowledges, the clearing house would essentially serve as a single patent pool for a given standard. Numerous patent pools exist to license SEPs on a wide variety of standards, and they are often touted as offering convenience and relative certainty. (Indeed, the fact that so many pools have successfully negotiated apportionment among their SEP owners indicates that the European Commission’s skepticism on such negotiations is likely overblown.) Option 5 also adopts characteristics of an intriguing litigation-based solution proposed in a 2017 paper by Jason Bartlett and Jorge Contreras titled, “Rationalizing FRAND Royalties: Can Interpleader Save the Internet of Things?” Like the Bartlett and Contreras proposal, Option 5 would apply a top-down approach and allow implementers to discharge their liability with a single royalty while SEP owners duke it out over the proper apportionment.

    It will be interesting to see how the various stakeholders react to the report’s discussion of Option 5 and whether this option makes its way into future drafts.

    Authors
    More insights

  • OIG Issues Favorable Advisory Opinion on Providing Gift Cards to Patients Who Complete Colon Cancer Screening Tests

    OIG Issues Favorable Advisory Opinion on Providing Gift Cards to Patients Who Complete Colon Cancer Screening Tests

    ARTICLE / CLIENT ALERT

    OIG Issues Favorable Advisory Opinion on Providing Gift Cards to Patients Who Complete Colon Cancer Screening Tests

    April 14, 2023

    Read time: 14 min

    Key takeaways
    Overview

    The US Department of Health and Human Services Office of Inspector General (OIG) recently issued Advisory Opinion (AO) 23-03, analyzing a proposed arrangement in which a company that manufactures an at-home colon cancer screening kit and its wholly-owned laboratory that performs the analysis (collectively, the Requestor) would furnish gift cards to certain patients to incentivize them to complete the sample collection process. Based on the facts and circumstances of the proposed arrangement, OIG reached a favorable conclusion, finding that the proposed arrangement would satisfy the Preventive Care Exception to the Beneficiary Inducement Civil Monetary Penalty (Beneficiary Inducements CMP) and otherwise presents low risk under the federal Anti-Kickback Statute (AKS). OIG also utilized AO 23-03 as an opportunity to clarify its position regarding the phrase “instruments convertible to cash,” as used in the Preventive Care Exception.

    In depth

    The furnishing of remuneration, whether in cash or kind (including by way of cash or gift cards), by healthcare providers and suppliers to federal health care program beneficiaries has long attracted scrutiny from OIG to the extent such remuneration may influence Medicare or Medicaid beneficiaries’ choice of a particular healthcare provider, practitioner or supplier, as well as induce beneficiaries to purchase items or services reimbursable by a federal health care program. However, OIG has acknowledged that in certain circumstances, remuneration may serve other, more beneficial purposes with respect to both beneficiaries and federal health care programs, particularly as it relates to encouraging preventive care and compliance with an established plan of care, which ultimately serves to lower costs. In this vein, OIG has adopted several exceptions to the general prohibition on furnishing remuneration to beneficiaries, including the Preventive Care Exception.

    The final determination reached in AO 23-03 is consistent with OIG’s prior positions on the applicability and scope of the Preventive Care Exception, though certain elements of the decision are noteworthy, particularly as it relates to the furnishing of gift cards to beneficiaries and the related analysis under the AKS.

    THE PROPOSED ARRANGEMENT IN AO 23-03

    The Requestor consists of a parent company that manufactures a proprietary, at-home colorectal cancer screening test and its wholly-owned subsidiary laboratory that analyzes the test. The test, which is only available to patients via a prescription, is the first and only US Food and Drug Administration-approved, non-invasive, stool-based DNA colorectal cancer screening test, and the laboratory is the only one capable of analyzing the test. When prescribed, a package containing the test kit is shipped directly to patients. Patients must collect their stool sample at home and ship the sample in a prepaid package back to the laboratory, which then analyzes the test to determine whether the sample has markers of colorectal cancer or advanced adenoma. A follow-up diagnostic colonoscopy is typically recommended for patients with positive results.

    The test is billable to Medicare, and the laboratory receives approximately $500 for each test it performs. Medicare covers the test once every three years for eligible beneficiaries.

    The Requestor noted that it maintains contact with patients throughout the process of shipping and collecting the sample, including phone calls, text messages, emails and other contact methods, to remind the patient to complete and return the sample. Despite these efforts, approximately 30% of patients do not return their samples to the laboratory. To incentivize patients to complete and return the sample, the Requestor asked OIG to evaluate a proposed arrangement pursuant to which if patients do not return the stool sample after two weeks and at least two patient outreaches, the Requestor would send a letter to the patient advising that they may receive a prepaid gift card (e.g., Visa or Mastercard) with a value of up to $75 if they return the stool sample by a specified deadline.

    The Requestor certified that the proposed arrangement would include a number of safeguards, namely: (1) patients would be told they could not use the gift cards for services provided by the Requestor; (2) patients could receive only one gift card per three-year period (i.e., the same time frame within which Medicare covers the test); (3) the Requestor would not promote or market the gift card to prescribers or patients; and (4) the Requestor would provide all patients with a gift card of the same dollar amount and not vary the gift card value based on patient demographics, the payor or the particular prescriber. Further, the gift card amount would be set at the “lowest amount less than or equal to $75 that significantly improves patient compliance.” The gift card could not be used to withdraw cash from an ATM or obtain cash back with another purchase. Finally, the gift card would not be available to patients who request the test through the Requestor’s website, whereby the Requestor connects patients with a provider to prescribe the test.

    As additional background, colorectal cancer is the second leading cause of cancer-related deaths in men and women. The Centers for Disease Control and Prevention (CDC) notes that colorectal cancer has the second-highest treatment cost of any cancer, resulting in about $24.3 billion in total annual healthcare costs. It is universally acknowledged that screening tests and early detection are essential to preventing and treating colorectal cancer. However, National Cancer Institute studies have found that only approximately 67% of high-risk adults are up-to-date on their colorectal cancer screenings.

    OIG ANALYSIS

    OIG determined that the proposed arrangement would implicate the Beneficiary Inducements CMP and the AKS, but ultimately concluded that the proposed arrangement would not constitute grounds for administrative sanctions, for the reasons set forth below.

    Beneficiary Inducements CMP

    The Beneficiary Inducements CMP provides for the imposition of civil monetary penalties against any person who offers or transfers remuneration to a beneficiary that the person knows or should know is likely to influence the beneficiary’s selection of a particular provider, practitioner or supplier for the order or receipt of any item or service for which payment may be made, in whole or in part, by Medicare or Medicaid.

    OIG determined that the proposed arrangement would implicate the Beneficiary Inducements CMP because the Requestor should know that the provision of gift cards would likely influence beneficiaries to return the sample to the laboratory for testing, which is ultimately reimbursable by Medicare or Medicaid. However, as referenced above, OIG promulgated several scenarios that are excluded from the definition of “remuneration” as that phrase is utilized in the Beneficiary Inducements CMP, including the Preventive Care Exception, which provides as follows:

    [ . . . ] The term ‘remuneration’ does not include:

    [ . . . ]

    (4) Incentives given to individuals to promote the delivery of preventive care services where the delivery of such services is not tied (directly or indirectly) to the provision of other services reimbursed in whole or in part by Medicare or an applicable State health care program. Such incentives include the provision of preventive care, but may not include –

    (i) Cash or instruments convertible to cash; or

    (ii) An incentive the value of which is disproportionally large in relationship to the value of the preventive care services (i.e., either the value of the service itself or the future health care costs reasonably expected to be avoided as a result of the preventive care).[1]

    The regulations further define “preventive care” for purposes of this exception as any service that is:

    (1) A prenatal service or a post-natal well-baby visit or is a specific clinical service described in the current U.S. Preventive Services Task Force’s Guide to Clinical Preventive Services, (the “USPSTF’s Guide”) and

    (2) Is reimbursable in whole or in part by Medicare or an applicable State health care program.[2]

    OIG concluded that the proposed arrangement satisfies this exception. In reaching this conclusion, OIG noted that the test meets the definition of “preventive care” as it is a clinical service described on the current US Preventive Services Task Force (USPSTF) Guide and is reimbursable by federal health care programs. OIG also concluded that although the incentive is in the form of a “cash equivalent” Visa or Mastercard gift card, the gift card (1) would not be an “instrument convertible to cash” (based on OIG’s clarification of that phrase’s meaning noted above), and (2) has a value that is not disproportionally large in relation to the value of the preventive care service itself. Based on these factors, the proposed arrangement meets the conditions of the Preventive Care Exception. Notably, OIG cautioned that the “value” of the incentive in relation to the value of the preventive service for purposes of this analysis is not necessarily limited to evaluating the preventive service’s Medicare reimbursable amount. Here, for example, OIG viewed the “value” of the test as including potential health benefits to beneficiaries and future healthcare costs that could be avoided as a result of the preventive care (i.e., the test).

    Further, OIG noted that although the test could result in beneficiaries obtaining additional reimbursable services (such as a follow-up colonoscopy), OIG determined that the test would not be “indirectly or directly tied” to the provision of these additional services. Although OIG did not delve into its analysis as to this conclusion, it has previously interpreted “tied” in this context as “conditioned upon.” Here, although the gift card may incentivize beneficiaries to follow through with the test, obtaining the test is not in and of itself conditioned upon the beneficiaries’ receipt of additional reimbursable items or services, even if the test may naturally lead to that.

    Based on these facts, OIG concluded that the gift card would not constitute “remuneration” under the Beneficiary Inducements CMP and thus would not constitute grounds for administrative sanctions.

    Anti-Kickback Statute

    Although OIG concluded that the proposed arrangement satisfies an exception to the Beneficiary Inducements CMP, OIG specifically noted that this does not “automatically render the Proposed Arrangement low risk” under the AKS. In its recently-released FAQ guidance, OIG restated its position that arrangements protected under a Beneficiary Inducements CMP exception are not “automatically” protected under the AKS (although AKS safe harbor compliance does result in Beneficiary Inducement CMP compliance). In practice, such arrangements tend to be lower risk under the AKS, since the facts and circumstances that satisfy the Beneficiary Inducements CMP exception are generally favorable factors in an AKS risk analysis. In AO 23-03 and the FAQ guidance, OIG takes the opportunity to remind the healthcare community that an analysis under both statutes is needed.

    The AKS, a criminal statute, prohibits knowingly and willfully offering, paying, soliciting or receiving any remuneration to induce, or in return for, referring an individual to a person for the furnishing of, or arranging the furnishing of, any item or service reimbursable by a federal health care program; or any remuneration to induce, or in return for, the purchasing, leasing or ordering of, arranging for or recommending the purchasing, leasing or ordering of any good, facility, service or item reimbursable by a federal health care program. Arrangements that induce beneficiaries to obtain preventive care may implicate the AKS to the extent the arrangement is intended to induce business reimbursable by federal health care programs. Here, OIG determined that the proposed arrangement implicates the AKS because the Requestor would offer and pay remuneration in the form of a cash equivalent gift card in an attempt to induce a beneficiary to return the test to the laboratory, resulting in the purchase of laboratory services reimbursable by federal health care programs.

    In evaluating arrangements related to preventive care, OIG considers, among other factors, (1) the nature and scope of the preventive care services; (2) whether the preventive care services are tied directly or indirectly to the provision of other items or services and, if so, the nature and scope of the other services; (3) the basis upon which patients are selected to receive the free or discounted services and (4) whether the patient is able to afford the services.

    Here, OIG concluded that the proposed arrangement would be unlikely to lead to improperly increased costs or overutilization of federal health care program services, largely because Medicare reimburses for colorectal screening only once every three years. The Requestor would offer the gift card only once every three years in line with the Medicare coverage timeline. OIG also found favorable the fact that the Requestor would not offer any incentives to prescribers of the test, nor would the prescribers be able to anticipate whether the Requestor would offer or ultimately provide a gift card to any of a prescriber’s patients (as gift cards are only offered to those patients who fail to return the test on a timely basis after the Requestor transmits multiple reminders). As such, OIG concluded that the proposed arrangement is unlikely to influence a prescriber to order the test in lieu of not ordering a test or ordering another screening test or procedure. Further, because the test is reimbursed at a fixed rate, the Requestor would not be able to pass on the cost of the gift card to the Medicare program.

    Second, OIG noted that the nature of the test and the condition it identifies were factors in its conclusion. Encouraging compliance with the test would align with recommended best practices for colorectal cancer screenings and reduce the significant 30% noncompliance rate. OIG noted that the collection of a stool sample can be unpleasant for patients (as opposed to a hair sample or a saliva sample), and thus a gift card may be more appropriate for encouraging completion of the test.

    Finally, OIG reiterated the Requestor’s other procedural safeguards, as described above, as additional reasons why the proposed arrangement ultimately presents low risk under the AKS.

    KEY TAKEAWAYS

    AO 23-03 offers one roadmap for companies interested in offering similar incentives to patients. However, OIG cautioned that different facts would likely have led to a different conclusion. Accordingly, structuring similar incentive arrangements will require careful analysis of the specific facts.

    For example, in this case, OIG determined that the $75 prepaid gift card was not disproportionate as compared to the $500 received by the Requestor for the preventive service, taking into account other significant values attributable to this particular service for beneficiaries and federal health care programs alike. Notably, OIG did not quantify the value of the “health benefits” or set a clear rule for comparing the value of remuneration versus the value of a billed service. As discussed above, colorectal cancer is an expensive and deadly disease, and early screening is essential, thus the “health benefits” in this case are clear and significant. Other health conditions or value comparisons would be subject to a similar facts and circumstances analysis and may not come out as favorably. OIG specifically noted that, under a different set of facts, a $75 incentive could be “disproportionately large” compared to a preventative care service billed at $500.

    OIG also took the opportunity to clarify its prior guidance on what it classifies as a “cash equivalent,” which it has long held as being a generally impermissible incentive for purposes of the Beneficiary Inducements CMP. Specifically, in prior guidance, OIG defined “cash equivalents” as including “items convertible to cash (such as a check) or that can be used like cash (such as a general purpose debit card, but not a gift card that can be redeemed only at certain stores for a certain purpose, like a gasoline gift card).” In AO 23-03, OIG clarified that the phrase “instruments convertible to cash” as utilized in the Preventive Care Exception is intended to refer to a subset of cash equivalents. Through this clarification, OIG provided a clear pathway for the use of a prepaid card (like a Visa or Mastercard) under the Preventive Care Exception. However, as OIG expressly noted, the analysis under the AKS is separate from the Beneficiary Inducements CMP and a Visa or Mastercard gift card is considered a “cash equivalent” for AKS purposes. Cash equivalent incentives would not qualify for the AKS patient engagement safe harbor and thus using cash equivalent gift cards still requires a thoughtful analysis of the purpose of the offer and other facts and circumstances.

    Additionally, note that OIG never opines on state law in its AOs. Some states have their own anti-kickback and beneficiary inducement statutes that may restrict or limit arrangements in a manner distinct from their federal counterparts. Thus, it is important to note that there may be a different risk profile under state law, even if an arrangement appears relatively low risk under federal law.

    Before entering into a similar arrangement, entities should consult legal counsel for a thoughtful analysis under both federal and applicable state law.

    Authors

    James A. Cannatti III

    Partner

    Washington, DC

    Jamie B. Gelfman

    Partner

    Miami

    Tony Maida

    Partner

    New York – One Vanderbilt Avenue

    Paul W. Radensky , MD

    Counsel

    Washington, DC, Miami

    Michael W. Ryan

    Partner

    Washington, DC

    Monica Wallace

    Partner

    Chicago

    Evelyn S. Atwater

    Associate

    Chicago

    More insights

  • And Then There Were Seven: Indiana Passes Consumer Privacy Bill

    And Then There Were Seven: Indiana Passes Consumer Privacy Bill

    ARTICLE / CLIENT ALERT

    And Then There Were Seven: Indiana Passes Consumer Privacy Bill

    April 14, 2023

    Read time: 7 min

    Key takeaways
    Overview

    With the end of several state legislative sessions on the horizon, it is perhaps unsurprising that we are seeing an uptick in state legislatures passing consumer (or health) data privacy laws. You can now count Indiana among the ranks of states passing such laws. The Indiana Consumer Data Protection Act (ICDPA) has passed both houses of the Indiana legislature and heads to Governor Eric Holcomb, who is expected to sign the bill. The ICDPA closely tracks the laws in Connecticut and Virginia, which is good news for many companies already subject to those laws. Another bit of good news is that the ICDPA will not go into effect until January 1, 2026, giving companies time to achieve compliance.

    Below we provide an overview of some of the key aspects of Indiana’s new consumer privacy law.

    In depth

    What Businesses Are Subject to the ICDPA? 

    Unlike California and Utah’s consumer privacy laws, the ICDPA does not include a revenue threshold. To be subject to the ICDPA, a business must either do business in Indiana or target products or services to Indiana consumers, and must do one of the following:

    • Control or process personal data of 100,000 or more Indiana consumers; or
    • Control or process personal data of 25,000 or more Indiana consumers and derive more than 50% of gross revenue from the sale of that data.

    Who Is a “Consumer”?

    In the ICDPA, a “consumer” is a natural person who is a resident of Indiana acting in a personal context. This means that employees and business-to-business contacts are expressly excluded from the definition of “consumer.”

    What Is “Personal Data”?

    “Personal data” in the ICDPA is “information that is linked or reasonably linkable to an identified or identifiable individual.” It excludes de-identified data, aggregate data and publicly available data. The limitations for de-identified data and publicly available data closely track those of Virginia (e.g., de-identification requires a public commitment to keep data de-identified, and public data includes both data from government files and data that is generally available through mass media sources).

    Although not expressly excluded from the definition of “personal data”, just as in Virginia, companies do not need to include pseudonymous data (under certain circumstances) when responding to consumer requests under the ICDPA.

    Who Can Enforce? 

    The Indiana Attorney General has exclusive enforcement authority, and an express provision disclaims any private right of action. Before initiating any enforcement proceeding, the attorney general must give 30 days’ written notice and an opportunity to cure to the controller. If an enforcement action follows, violations of the ICDPA are subject to fines of up to $7,500 per violation.

    Who Is Exempt?

    The ICDPA’s exemptions closely mimic those of other state privacy laws. For example, personal information covered by laws such as the Health Insurance Portability and Accountability Act, the Children’s Online Privacy Protection Act (COPPA), the Gramm-Leach-Bliley Act, the Family Educational Rights and Privacy Act and a litany of other federal laws is exempt.

    In addition, the ICDPA does not apply to government entities, nonprofit organizations or higher education institutions.

    The ICDPA also exempts the use of personal data for certain specific purposes, such as compliance with law, preventing fraud or injury to others, and defending legal claims (just as in Virginia).

    What Obligations Are Imposed?

    The ICDPA imposes what have become “standard” obligations on data controllers under state consumer privacy laws. Specifically, controllers must:

    • Limit the purpose of processing personal data to that which is reasonably necessary and proportional;
    • Take steps to implement reasonable safeguards for the personal data within their control;
    • Refrain from discriminating against consumers for exercising their rights and from processing personal data in violation of federal laws that prohibit discrimination;
    • Be transparent in their reasonably accessible, clear and meaningful privacy notice; and
    • Ensure that contracts control relationships with their processors (note: the law itself details the minimum necessary provisions of these contracts).

    What Consumer Rights Are Created by the ICDPA?

    Controllers must provide a limited but standard set of consumer rights to Indiana consumers:

    • Opt-out rights related to the sale of personal data, targeted marketing and profiling (automated decision making that could have significant legal effects, such as those related to housing, drinking water, credit, etc.);
    • Deletion rights (with respect to the data provided by or about the consumer);
    • Access rights, including a right to confirm whether a controller is processing any data at all;
    • Correction rights, but limited to data the consumer previously provided;
    • Appeal rights; and
    • Data portability rights, but limited to data the consumer previously provided (controllers are given the option to respond to a data portability request with a “representative summary” of the personal data held rather than the data itself).

    Sensitive Personal Information

    Under the ICDPA, “sensitive data” is considered personal data that includes information such as racial/ethnic origin, religious beliefs, mental or physical health diagnoses made by a healthcare provider, sexual orientation, citizenship or immigration status, genetic or biometric information used to uniquely identify an individual, personal data collected from a known child (under the age of 13) and precise geolocation (location within a radius of 1,750 feet). Under the ICDPA, controllers may not process (including collection) sensitive data without obtaining the consumer’s consent or, in the case of a child, complying with COPPA.

    Response to Consumer Inquiries

    As has become relatively standard in state consumer privacy laws, controllers must respond to a consumer personal data request within 45 days of receipt of the request, with a 45-day extension available. If a consumer appeals a controller’s decision to deny the consumer’s request, the appeal response must be delivered within 60 days. As in Virginia, if the appeal is denied, controllers must provide the consumer with a method for contacting the attorney general.

    Data Protection Impact Assessments

    As under the laws on which the ICDPA is modeled, controllers must document impact assessments before they engage in various processing activities, including the following:

    • Processing for targeted marketing;
    • Sale of personal data;
    • Processing of personal data for profiling if the profiling presents a reasonably foreseeable risk of legal, deceptive, discriminatory, financial, reputational or physical harms;
    • Processing sensitive data; and
    • A catch-all category of “any processing activities involving personal data that present a heightened risk of harm to consumers.”

    As in Virginia, Colorado, Connecticut and elsewhere, these impact assessments must analyze the benefits of the processing to the company, consumer and public, while weighing the harms and potential mitigants. Thankfully, the ICDPA allows for the use of impact assessments done under other state laws to count towards the requirements of ICDPA and does not require retroactive impact assessments for processing activities occurring prior to the effective date of the law.

    When Does the ICDPA Take Effect?

    The ICDPA comes into effect on January 1, 2026.

    ***

    Creating a successful, effective and comprehensive privacy program for your organization requires a thorough understanding of both the relevant legal obligations and the personal data subject to compliance. Setting up a program that is prepared to respond to various state privacy laws as they come into effect will save organizations time in the long run, especially as many of these laws reflect one another.

    If you have questions or need assistance in readiness work for the new state consumer laws, please contact your regular McDermott lawyer or reach out to David P. Saunders or Jonathan Ende.

    Authors

    David P. Saunders

    Partner

    Chicago

    Jonathan Ende

    Partner

    Washington, DC

    More insights

  • Value-Based Care Symposium 2023

    Value-Based Care Symposium 2023

    ARTICLE

    Value-Based Care Symposium 2023

    April 13, 2023

    Read time: 2 min

    Key takeaways
    Overview

    The Value-Based Care Symposium 2023 was packed with unique panels and invigorating discussions around the most critical business and policy issues facing companies in the value-based care space. Check out the key takeaways below for insights from the conference.

    In depth
    Authors
    More insights

  • Washington Legislature Passes My Health My Data Act

    Washington Legislature Passes My Health My Data Act

    ARTICLE / CLIENT ALERT

    Washington Legislature Passes My Health My Data Act

    April 13, 2023

    Read time: 9 min

    Key takeaways
    Overview

    Washington State’s My Health My Data Act (the Act), which is working its way through the reconciliation process after the Washington Senate and House passed different versions of the Act, is ultimately expected to be signed into law by Governor Jay Inslee this year. This privacy law differs from other recent state privacy legislation in that it is singularly focused on non-Health Insurance Portability and Accountability Act (HIPAA)-regulated consumer health data. Moreover, the bill contains provisions applicable to processors and even third parties who may come into contact with a broadly defined set of “consumer health data,” not just those companies operating healthcare-adjacent businesses. The Act could have a significant impact on advertisers, mobile app providers, wearable device manufacturers and, of course, healthcare companies and their data processors handling non-HIPAA-regulated health information. Below, we examine several key aspects of the Act that are similar in both the House and Senate versions of the bill.

    In depth

    APPLICABILITY 

    The Act will apply to any entity, including nonprofits, that conducts business in Washington, or that provides products and services to consumers in Washington, and alone or jointly with others determines the purpose and means of collecting, processing, sharing or selling consumer health data. For purposes of the Act, a “consumer” does not include an individual acting in an employment or business-to-business context.

    WHAT IS “CONSUMER HEALTH DATA”?

    The Act defines “consumer health data” as personal information (as defined by the Act, and which expressly includes “Cookie ID,” picking up on recent Office for Civil Rights guidance and Federal Trade Commission (FTC) enforcement actions regarding the use of ad tech by healthcare entities and digital health services) that is linked or reasonably linkable to a consumer and that identifies the consumer’s past, present, or future physical or mental health status. Consumer health data specifically includes:

    • Individual health conditions, treatment, diseases or diagnoses;
    • Social, psychological, behavioral and medical interventions;
    • Health-related surgeries or procedures;
    • Use or purchase of prescribed medication;
    • Bodily functions, vital signs, symptoms or measurements of the information expressly identified in the definition of consumer health data;
    • Diagnoses or diagnostic testing, treatment or medication;
    • Gender-affirming care information (as defined by the Act);
    • Reproductive or sexual health information (as defined by the Act);
    • Biometric data (as defined by the Act);
    • Genetic data (as defined by the Act);
    • Precise location information (as defined by the Act) that could reasonably indicate a consumer’s attempt to acquire or receive health services or supplies;
    • Data that identifies a consumer seeking healthcare services (as defined by the Act); and
    • Any information that a regulated entity, or its respective processor, processes to associate or identify a consumer with the data described above that is derived or extrapolated from non-health information (such as proxy, derivative, inferred or emergent data by any means, including algorithms or machine learning).

    Importantly, the Act defines healthcare services broadly to mean any service provided to a person to assess, measure, improve or learn about a person’s mental or physical health. As a result, businesses providing services ancillary to clinical care, such as nutrition programs or social care services, or facilitating connections between consumers and such service providers, could have responsibilities under the Act.

    EXEMPTIONS AND CARVE-OUTS

    As with other state consumer privacy laws, the Act has several entity-type and data-type exemptions. For example, the Act will not apply to:

    • Government agencies, tribal nations or contracted service providers when processing consumer health data of a governmental agency;
    • Protected Health Information (PHI) governed by HIPAA, information intermingled with PHI maintained by HIPAA-regulated entities, and health records governed by or created pursuant to other healthcare-related state and federal laws (e.g., 42 CFR part 2, UHCIA, federal regulations regarding human subjects research, and federal and state peer review laws, public health reporting requirements, patient safety and other healthcare quality improvement activities); and
    • Data regulated by the Gramm-Leach-Bliley Act, Fair Credit Reporting Act, Administrative Simplification provisions of the Social Security Act (42 U.S.C. 1320d et seq.), Family Educational Rights and Privacy Act, statutes and regulations applicable to the Washington Health Benefit Exchange and certain privacy rules adopted by the Washington Office of the Insurance Commissioner.

    The Act does not apply to “deidentified data,” which is defined as data that cannot reasonably be used to infer information about, or otherwise be linked to, an identified or identifiable consumer, or a device linked to such a consumer, so long as the regulated entity or the small business that possesses such data (1) takes reasonable measures to ensure that such data cannot be associated with a consumer, (2) publicly commits to process such data only in a deidentified fashion and not attempt to reidentify such data and (3) contractually obligates recipients of such data to satisfy criteria described in (1) – (3).

    DATA CONTROLLER OBLIGATIONS

    The Act will require regulated companies—even those already subject to other state consumer privacy laws—to add still more privacy disclosures to their website, and take additional steps to, for example, obtain consent from customers when handling their consumer data. Specifically, the Act will require regulated companies to:

    • Maintain and publish on their website a consumer health data privacy policy that discloses (1) the categories of consumer health data collected and the purposes of collection, (2) the categories of sources from which consumer health data is collected, (3) the categories of consumer health data that is shared and the categories of third parties and specific affiliates with whom the regulated entity shares consumer health data and (4) how a consumer may exercise consumer rights with regard to consumer health data;
    • Except for limited circumstances, obtain a consumer’s consent before collecting or sharing consumer health data. “Sharing” as used in the Act means the disclosure of any health data to a third party or to a corporate affiliate, with certain limited exceptions to, for example, fulfill the request of a consumer;
    • Establish, implement and maintain reasonable administrative, technical and physical data security practices to protect consumer health data, including internal enterprise-wide access controls designed to restrict access to consumer health data only to those employees, processors or contractors that need access to further the purposes of the collection; and
    • Enter into a written contract with data processors related to their use of consumer health data.

    OTHER KEY RESTRICTIONS

    In addition to the obligations imposed on regulated entities, the Act also contains provisions that make it unlawful for any person or entity to:

    • Sell consumer health data without first obtaining authorization that is written in plain language, contains the information specified by the Act, and is separate from consent obtained to collect or share consumer health data in the first place; and
    • Implement a geofence around an entity that provides in-person healthcare services, if the geofence is used to (1) identify or track consumers seeking healthcare services; (2) collect consumer health data from consumers; or (3) send notifications, messages or advertisements to consumers related to their consumer health data or healthcare services.

    CONSUMER RIGHTS

    Consumers have a number of privacy rights under the Act, including:

    • Confirm whether a regulated entity is collecting, sharing or selling consumer health data;
    • Access consumer health data, including a list of all third parties and affiliates with whom the regulated entity has shared or sold the consumer health data;
    • Withdraw consent from the regulated entity’s collection and sharing of consumer health data;
    • Have consumer health data deleted; and
    • Appeal a regulated entity’s refusal to act on one of the consumer’s rights above.

    New in the Act is a requirement that data on archived or backup systems must be deleted within six months of the deletion request, without any exceptions. This will likely cause operational headaches and potentially be commercially or technically infeasible for many companies. For all other requests and consumer appeals, regulated entities must act on a request without undue delay and within 45 days (and subject to a one-time 45-day extension). And any verified consumer request must also be pushed downstream to all service providers, contractors, third parties and affiliates.

    AG ENFORCEMENT AND PRIVATE RIGHT OF ACTION

    Violations of the Act are enforceable under the Washington Consumer Protection Act (CPA) as unfair or deceptive acts in trade or commerce and unfair methods of competition. The CPA may be enforced by the Washington Attorney General. However, the Act also permits a private right of action for aggrieved consumers. Civil penalties for unfair or deceptive trade acts and unfair competition under the CPA can rise to $7,500 per violation but can also include treble damages, capped at $25,000, in civil actions brought by consumers.

    ISSUES TO BE RESOLVED

    While the House and Senate versions of the bill are substantially similar, a few key issues still need to be resolved through reconciliation.

    • The House version would take effect 90 days after the current legislative session expires, which would be late July 2023, while the Senate version would take effect on March 31, 2024.
    • The Senate bill includes a limited small business exemption while the House bill does not. Under the Senate version, entities that (1) collect, process, sell or share consumer health data of fewer than 100,000 consumers (defined as either Washington residents or an individual whose health data is collected in Washington) during a calendar year, or (2) control, process, sell or share consumer health data of fewer than 25,000 consumers and derive less than 50% of gross revenue from the collection, processing, selling or sharing of consumer health data, are considered “small businesses” and would not be required to comply with the Act until June 30, 2024.

    TAKEAWAYS

    Given the Act’s broad scope and applicability, many businesses may for the first time need to implement compliance activities regarding the collection, use and disclosure of consumer health data and responding to consumer rights requests. This will include posting another privacy disclosure on websites, creating new consent and authorization forms, implementing internal firewalls to limit access to data and evaluating the feasibility of compliance with, e.g., the Act’s onerous deletion requirements.

    If you have questions or need assistance getting ready for the Act or other new state privacy laws, please contact any authors or your regular McDermott lawyer.

    Authors

    David P. Saunders

    Partner

    Chicago

    Sam Siegfried

    Partner

    Chicago

    More insights

  • Preliminary Injunction, Meet Irreparable Harm

    Preliminary Injunction, Meet Irreparable Harm

    ARTICLE

    Preliminary Injunction, Meet Irreparable Harm

    Apr 13, 2023

    Read time: 4 min

    Key takeaways
    Overview

    The US Court of Appeals for the Fifth Circuit, in a case where an ex-employer sought preliminary injunctive relief based on an alleged breach of non-disclosure and non-compete agreements and alleged misappropriation of confidential business information, ruled that the Texas presumption of irreparable harm for breach of non-compete clauses does not always apply and that a finding of irreparable harm requires particularized findings regarding the alleged harm. Direct Biologics L.L.C. v. McQueen, Case No. 22-50442 (5th Cir. April 3, 2023) (Davis, Dennis, JJ., Higginson, C.J.).

    Adam McQueen previously was executive vice president of Direct Biologics (DB). As a member of DB’s management, McQueen had access to DB’s confidential trade secret information regarding the production and production specifications of DB’s novel medical technologies. To protect that information, McQueen signed both non-compete and non-disclosure agreements with DB, preventing him from providing “services . . . similar to that which [he] provided to [DB],” and from disclosing or using DB’s confidential information.

    McQueen resigned from his position and joined Vivex, DB’s direct competitor. Almost immediately DB sued McQueen and Vivex, alleging breach of the non-compete, breach of the non-disclosure agreement and trade secret misappropriation. Shortly thereafter, DB moved for a preliminary injunction to compel McQueen to comply with the non-compete covenant and prevent him from using DB’s confidential and trade secret information. Vivex countered by arguing that McQueen’s new role as vice president of product strategy was a “non-competitive role,” and that McQueen was sequestered from all products that would compete with DB. The district court denied the preliminary injunction motion, agreeing with Vivex that DB failed to provide any evidence that DB had been harmed. DB appealed.

    DB argued that the district court erred in two ways—first, by failing to apply Texas’s presumption of irreparable harm based on McQueen’s breach of a non-compete agreement, and second, by failing to correctly apply the irreparable harm analysis by looking only at past actions.

    The Fifth Circuit began by reviewing Texas’s presumption of irreparable harm. Under Texas law, the breach of a non-compete agreement can result in a presumption of irreparable harm. But, as the Court explained, the presumption does not always apply. Texas courts can decline to apply the presumption when there is no independent proof of harm. Here, not only did DB fail to produce any evidence that McQueen disclosed or used DB’s confidential information, but there also was evidence showing that he had not. Based on this record, the Court held that it was not an abuse of discretion to decline to apply the presumption.

    The Fifth Circuit then analyzed the district court’s irreparable harm analysis. The Court explained that the irreparable harm analysis requires that the trial court make particularized findings regarding whether the harm was likely to occur over the pendency of the litigation, and if so, whether the harm would be difficult to quantify monetarily. While the district court here made findings directed to whether McQueen had caused harm, it did not make any findings regarding what might happen during the litigation. The district court also did not make any findings directed to whether any damages from harm caused during the litigation could be quantified.

    The Fifth Circuit, therefore, remanded the case back to the district court to make particularized findings regarding whether harm was likely to occur, and, if so, whether any such misuse would result in difficult-to-quantify damages.

    Authors
    More insights
    Endnotes

  • Medicare Providers Take Note: Stark Law-Related Changes from CMS

    Medicare Providers Take Note: Stark Law-Related Changes from CMS

    ARTICLE / REPORT

    Medicare Providers Take Note: Stark Law-Related Changes from CMS

    April 11, 2023

    Read time: 3 min

    Overview

    In the last few months, the US Centers for Medicare & Medicaid Services (CMS) has made several noteworthy changes and provided a material clarification for providers and suppliers who are subject to the federal physician self-referral law (commonly referred to as the Stark Law). First, recognizing that certain aspects of the submission protocol have been identified as burdensome by stakeholders, CMS streamlined its voluntary self-disclosure process for certain disclosing parties, significantly reducing the number of forms needed to comply with the Stark Law Voluntary Self-Referral Disclosure Protocol (SRDP). Additionally, CMS updated and created new forms under the SRDP, the use of which, effective as of March 1, 2023, is now required. Separately, CMS also recently revised its process for updating its Stark Law code list, which formally defines certain service codes within four categories as designated health services (DHS) under the Stark Law. While updates to the DHS code list are generally released without much fanfare, CMS’s regular annual updates to the Stark Law code list have also changed the scope of services and providers who are subject to the Stark Law. Finally, CMS provided an important clarification that may affect the ability of providers and suppliers to reconcile payment discrepancies more than 90 days after a compensation arrangement has ended.

    In depth
    Tabs

    Nicholas F. Alarif

    Partner

    Washington, DC

    Caroline Reignley

    Partner

    Washington, DC

    More insights
    Endnotes

  • Physician Practice Management and ASC Symposium 2023

    Physician Practice Management and ASC Symposium 2023

    ARTICLE

    Physician Practice Management and ASC Symposium 2023

    April 11-12, 2023

    Read time: 2 min

    Key takeaways
    Overview

    The Physician Practice Management and ASC Symposium 2023 brought together the top voices in healthcare and private equity along with McDermott’s preeminent healthcare and corporate lawyers for candid conversations centered on succeeding in today’s deal-making environment. Check out the key takeaways below for insights from the conference.

    In depth

    Click on the links below to view key takeaways and presentations from the Physician Practice Management and ASC Symposium 2023. Key takeaways will be posted as they become available.

    Questions about your next PPM-ASC investment, acquisition or collaboration? Get in touch.

    Plenary Sessions

    Navigating the Turbulence in the Provider Deal Market and Positioning Provider Business for Growth

    State of the PPM Industry: Perspectives from Top CEOs

    The Evolution of ASC Management Companies

    CDO Perspective: Development and Acquisition Strategies for Effective Growth

    The Latest on Physician Compensation and Alignment Strategies

    Washington Outlook: Evolving Federal Policy Impacting Reimbursement, Operations and Deal Strategies


    Breakouts

    PPM, ASC and Health System Collaborations and Innovation

    Leveraging Data Collaborations for Revenue Growth

    Specialty Spotlight: Cardiology

    Fraud and Abuse Risk Mitigation and Enforcement Trends

    Specialty Spotlight: Women’s Health/Fertility

    Specialty Spotlight: Gastroenterology

    Specialty Spotlight: Urology

    ASC 2.0 Selected Trends: Bundled Payments, Tech and Anesthesia

    Trends in Value-Based Care Models

    Specialty Spotlight: Orthopedics/Physical Therapy

    Maximizing Managed Practice Value and Operations

    Specialty Spotlight: Behavioral Health

    Authors
    More insights

  • First Look at the EU’s Draft Regulations on SEP Licensing

    First Look at the EU’s Draft Regulations on SEP Licensing

    ARTICLE / CLIENT ALERT

    First Look at the EU’s Draft Regulations on SEP Licensing

    April 11, 2023

    Read time: 6 min

    Key takeaways
    Overview

    In late March, news broke that the European Commission was drafting sweeping regulations on the licensing of standard essential patents (SEPs). Commentators predict the draft will be released in late April. McDermott has had the opportunity to review the regulations and, although this is an early draft that will likely evolve, we offer the following initial observations.

    In depth

    DETAILS OF THE DRAFT REGULATIONS

    In its current form, the new regulatory framework would encourage increased transparency in SEP licensing through several new policies and procedures. In particular, the regulations would establish a “competence center” at the European Union Intellectual Property Office (EUIPO) to act as a sort of clearinghouse for SEP issues (both technical and economic). The EUIPO does not currently have patent expertise; EP patents are currently the purview of the European Patent Office (EPO), which is separate from the European Union and includes non-EU members.

    The competence center would be tasked with:

    • Maintaining a register of SEPs
    • Maintaining a database of SEP case law and determinations of “fair, reasonable and non-discriminatory” (FRAND) terms and royalties
    • Assessing the essentiality of SEPs
    • Administering aggregate FRAND royalty determinations
    • Administering individual FRAND rate determinations.

    Importantly, before enforcing its SEPs in any European court (including the Unified Patent Court), a SEP owner would be required to register its SEPs with and obtain an assessment of the FRAND rate from the EUIPO (although the current draft includes loopholes that could allow a SEP owner to avoid the latter requirement in certain circumstances). SEP registration would be a rather straightforward matter. The FRAND rate determination, however, would be a formal mediation-style process presided by two “conciliators” and involve limited discovery, written submissions, witnesses (including experts) and potentially an oral hearing. The draft places a nine-month time limit on the FRAND rate determination and the costs would be borne by both parties.

    The EUIPO will also conduct essentiality checks of select claimed SEPs. Such a check would be performed by an anonymous evaluator. A SEP owner may propose up to 100 of its SEPs to be checked for essentiality, and the EUIPO will annually select a sample of SEPs from each owner and each standard for checks. The SEP owner may have multiple opportunities to file observations and responses to third-party observations during the essentiality check process. The role of third parties (such as potential implementers of a standard), however, would be limited to filing observations on SEPs already chosen for an essentiality check and requesting “peer evaluation” of the results. The SEP owner would bear the cost of essentiality checks. Although not legally binding, the regulations explicitly state that an essentiality check can be used as evidence in subsequent negotiations and litigation. An essentiality check would not, however, be a prerequisite for enforcing a SEP. Interestingly, the draft regulations would require the EUIPO to register preexisting essentiality checks conducted by an independent evaluator.

    The process of determining an aggregate FRAND royalty to apply to the entire standardized technology would be largely driven by SEP owners. An unspecified number of “contributors to a standard” can notify the EUIPO about an aggregate royalty by submitting specified information, including a proposed aggregate royalty, within 90 days after the release of the standard. This notification can later be revised by the SEP owners. Additionally, on request of 10% of all contributors to a standard within a specified timeframe after the release of the standard, the EUIPO will mediate discussions for an aggregate royalty. At least 5% of contributors and/or five implementers can request a nonbinding expert opinion on the aggregate royalty from the EUIPO. The relevant standard-setting organization and stakeholders (including SEP owners and implementers) would be notified of such a request and any stakeholder could participate in the process (e.g., by submitting information to the panel of conciliators assigned to issue the opinion). The regulations explicitly state that SEP owners should consider giving micro-, small- and medium-sized enterprises more favorable terms, however, terms would not be considered in determining FRAND for larger entities. On this point, the regulations appear to be inconsistent with the commitment that FRAND licensing be non-discriminatory and that each licensee (whether large or small) be treated similarly. For example, in its recent InterDigital v. Lenovo opinion, the UK High Court of Justice explicitly rejected a SEP owner’s disparate treatment of small and large entities to be non-FRAND.

    COMMENTS ON THE DRAFT REGULATIONS’ IMPACT

    Overall, both SEP owners and implementers would benefit from the increased transparency these regulations could bring to FRAND negotiations. Some aspects favor SEP implementers. For example, the requirement that a SEP owner would need to obtain a FRAND determination from the EUIPO before demanding FRAND royalties or enforcing its SEPs would add delay and risk to the enforcement process. By requesting that SEP holders agree to an aggregate royalty, the European Commission is signaling a preference for a top-down FRAND royalty calculation, which is typically preferred by implementers because it allows them to calculate the total aggregate royalties that will need to be paid when implementing a particular standard. For these reasons, the new regulations could steer SEP owners away from European venues.

    That said, the draft also offers benefits to SEP owners. The proposed nine-month timeline for FRAND rate mediation is substantially faster than most SEP license negotiations. The essentiality checks and aggregate FRAND royalty determination are driven primarily by SEP owners, with only limited input from implementers.

    This is an interesting development, but it is important to remember that the draft is in its early stages still. Whether it will come into force, including with any amendments, is rather unpredictable. Commentators have already flagged potential constitutional issues with the draft that will need to be sorted out in the coming months (and years). Nevertheless, it appears that SEP owners and implementers are already mobilizing in an effort to lobby European legislators to support and/or critique the regulations.

    Authors

    Dr. Boris Uphoff

    Partner

    Munich, Düsseldorf

    Amol Parikh

    Partner

    Chicago

    Aashish Kapadia

    Partner

    Austin

    More insights

  • Iowa’s New Privacy Law: The Basics

    Iowa’s New Privacy Law: The Basics

    ARTICLE / CLIENT ALERT

    Iowa’s New Privacy Law: The Basics

    April 10, 2023

    Read time: 6 min

    Key takeaways
    Overview

    As expected, the number of state consumer privacy laws continues to rise. Joining the ranks of California, Colorado, Connecticut, Utah and Virginia is now Iowa. On March 28, 2023, Iowa’s Governor signed the Iowa Data Privacy Act into law, which will go into effect on January 1, 2025. The Hawkeye State’s law closely mirrors Utah’s law, and it deviates in some of the same ways that Utah did from the model in Colorado, Connecticut and Virginia. The bad news, therefore, is growing discordance among the states as to a “model” for state consumer privacy bills. We now have California with its own model, Colorado, Connecticut and Virginia substantively aligned on most major items, and Utah and Iowa in a third camp. Iowa’s new law serves as yet another reminder of why having a federal consumer privacy bill, with preemption, could be critical to easing the compliance burden on companies.

    Back to Iowa, those already in compliance or working towards compliance with the laws of the other states’ privacy laws may find it straightforward to incorporate the obligations of Iowa’s new law and have until 2025 to become compliant. Below we provide an overview of some of the key aspects of Iowa’s new consumer privacy law.

    In depth

    To whom does Iowa’s Data Privacy Act (IDPA) apply to? 

    Unlike California and Utah, the IDPA does not include a revenue threshold. To be subject to the IDPA, a business must do business in Iowa or target products or services to Iowa consumers and either…

    1. Control or process personal data of 100,000 or more Iowa consumers; or
    2. Control or process personal data of 25,000 or more Iowa consumers and derive over 50% of gross revenue from the sale of that data.

    Who is a “consumer”?

    In the IDPA, a “consumer,” is a natural person who is a resident of Iowa acting in a personal (noncommercial and nonemployment) context. This means that employees and B2B contacts are expressly excluded from the definition of “consumer”; this is similar to all other state laws except for California.

    Who can enforce the IDPA? 

    The Iowa Attorney General has exclusive enforcement authority, and there is an express provision disclaiming any private right of action. Before initiating any enforcement proceeding, the Attorney General must give 90 days’ written notice and an opportunity to cure to the controller. If an enforcement action follows, violations of the IDPA can be up to $7,500 per violation.

    Who is exempt?

    The exemptions of the IDPA closely mimic those of other state privacy laws. For example, personal information covered by laws such as the Health Insurance Portability and Accountability Act (HIPAA), the Children’s Online Privacy Protection Act (COPPA), the Gramm-Leach-Bliley Act, the Family Educational Rights and Privacy Act and a litany of other federal laws.

    In addition, the IDPA does not apply to government entities, nonprofit organizations or higher education institutions.

    What obligations are imposed?

    The IDPA imposes what should now be considered “standard” obligations on data controllers in jurisdictions with consumer privacy laws. That means controllers subject to the IDPA must:

    1. Limit the purpose of processing personal data to that which is reasonably necessary and proportional;
    2. Take steps to implement reasonable safeguards for the personal data within their control;
    3. Refrain from discriminating against consumers for exercising their rights and from processing personal data in violation of federal laws that prohibit discrimination;
    4. Be transparent in their reasonably accessible, clear and meaningful privacy notice; and
    5. Ensure contracts control relationships with their processors (note: the law itself details the minimum necessary provisions of these contracts).

    What is not there?

    The IDPA does not include certain features of other state consumer privacy laws, including, for example:

    • No data protection or privacy risk assessment requirements.
    • No consumer right to correct.
    • No specific language around automated decision making.

    What consumer rights are created by the IDPA?

    Controllers must provide a limited, but standard, set of consumer rights to Iowa consumers:

    1. Opt-out rights (to the sale of personal data, targeted marketing and the use of sensitive personal information for nonexempt purposes);
    2. Deletion rights (with respect to the data provided by the consumer);
    3. Access rights (including a right to confirm whether the controller is processing any data at all);
    4. Appeal rights; and
    5. Data portability rights.

    Sensitive Personal Information

    Under the IDPA, “sensitive information” is considered personal data that includes information such as racial/ethnic origin, religious beliefs, mental or physical health diagnosis, certain uses of citizenship status, information from a known child and geolocation data within a 1,750-foot radius, among others. Controllers must provide clear notice and an opportunity to the consumer to opt out of nonexempt processing. With respect to the sensitive data collected from a known child, data controllers must abide by COPPA obligations.

    So, what is nonexempt processing? That phrase is not defined in the IDPA, but likely refers to those internal data uses expressly permitted in Section 7 of the IDPA, including, for example, compliance with state law, fraud detection and other internal data uses.

    Respond to consumer inquires

    Controllers must respond to a consumer personal data request within ninety (90) days of receipt of the request, with a forty-five (45) day extension available. This is a longer period of time for response than in any of the other states that have passed consumer privacy laws. If a consumer appeals a decision of the controller to deny a consumer request, the appeal response must be delivered within sixty (60) days.

    When does the IDPA take effect?

    The IDPA comes into effect on January 1, 2025.

    ***

    Creating a successful and effective, comprehensive privacy program for your organization requires a thorough understanding of both the relevant legal obligations and the personal data subject to compliance. Setting up a program that is prepared to respond to various state privacy laws as they come into effect will save organizations time in the long run, especially as many of these laws reflect one another.

    If you have questions or need assistance in readiness work for the new state consumer laws, please contact your regular McDermott lawyer or reach out to David Saunders or Allison Tassel.

     

    Authors

    David P. Saunders

    Partner

    Chicago

    More insights